Log in
(Ad)
What a cool story coming out of The War Room today. One of the members made a trade on Bryan's recommendation... went to get a cup of coffee... and closed out a 33% win by the time he got back! That's more than most people make in a year! You CANNOT miss out on these wins anymore.

NASDAQ:ALBO - Albireo Pharma Stock Price, Forecast & News

$23.65
-0.38 (-1.58 %)
(As of 01/24/2020 09:20 AM ET)
Today's Range
$23.10
Now: $23.65
$23.96
50-Day Range
$20.21
MA: $24.18
$28.98
52-Week Range
$16.13
Now: $23.65
$38.69
Volume156,793 shs
Average Volume80,695 shs
Market Capitalization$300.12 million
P/E RatioN/A
Dividend YieldN/A
Beta1.56
Albireo Pharma, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders in the United States. Its lead product candidate is A4250, an orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating progressive familial intrahepatic cholestasis and phase II clinical trial for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ALBO
CUSIPN/A
Phone857-254-5555

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$12.74 million
Book Value$10.24 per share

Profitability

Net Income$-46,110,000.00
Net Margins-1,881.86%

Miscellaneous

Employees39
Market Cap$300.12 million
Next Earnings Date3/5/2020 (Estimated)
OptionableOptionable

Receive ALBO News and Ratings via Email

Sign-up to receive the latest news and ratings for ALBO and its competitors with MarketBeat's FREE daily newsletter.


Albireo Pharma (NASDAQ:ALBO) Frequently Asked Questions

What is Albireo Pharma's stock symbol?

Albireo Pharma trades on the NASDAQ under the ticker symbol "ALBO."

How were Albireo Pharma's earnings last quarter?

Albireo Pharma Inc (NASDAQ:ALBO) issued its earnings results on Wednesday, November, 6th. The biopharmaceutical company reported ($1.73) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.55) by $0.18. The biopharmaceutical company earned $1.39 million during the quarter, compared to analyst estimates of $1.38 million. Albireo Pharma had a negative net margin of 1,881.86% and a negative return on equity of 62.69%. View Albireo Pharma's Earnings History.

When is Albireo Pharma's next earnings date?

Albireo Pharma is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Albireo Pharma.

What price target have analysts set for ALBO?

4 analysts have issued 1-year price targets for Albireo Pharma's stock. Their forecasts range from $39.00 to $69.00. On average, they expect Albireo Pharma's stock price to reach $56.67 in the next twelve months. This suggests a possible upside of 139.6% from the stock's current price. View Analyst Price Targets for Albireo Pharma.

What is the consensus analysts' recommendation for Albireo Pharma?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Albireo Pharma in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Albireo Pharma.

Has Albireo Pharma been receiving favorable news coverage?

News articles about ALBO stock have been trending very positive recently, InfoTrie reports. The research group identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Albireo Pharma earned a news impact score of 3.9 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the near term. View News Stories for Albireo Pharma.

Are investors shorting Albireo Pharma?

Albireo Pharma saw a increase in short interest during the month of December. As of December 31st, there was short interest totalling 791,600 shares, an increase of 6.0% from the December 15th total of 746,900 shares. Based on an average trading volume of 72,500 shares, the days-to-cover ratio is presently 10.9 days. Approximately 7.8% of the shares of the company are sold short. View Albireo Pharma's Current Options Chain.

Who are some of Albireo Pharma's key competitors?

What other stocks do shareholders of Albireo Pharma own?

Who are Albireo Pharma's key executives?

Albireo Pharma's management team includes the folowing people:
  • Mr. Ronald H. W. Cooper, CEO, Pres & Director (Age 56)
  • Ms. Martha J. Carter, Chief Regulatory Officer (Age 67)
  • Dr. Paresh N. Soni, Consultant (Age 59)
  • Dr. Per-Goran Gillberg, Co-Founder & VP of Devel.
  • Mr. Simon Harford, CFO & Treasurer

Who are Albireo Pharma's major shareholders?

Albireo Pharma's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Chicago Capital LLC (1.38%) and Alpine Global Management LLC (0.10%). Company insiders that own Albireo Pharma stock include Jan Mattsson, Life Sciences Maste Perceptive, Patrick Taylor Horn, Phase4 Partners Ltd, Ronald Harold Wilfred Cooper and Simon NR Harford. View Institutional Ownership Trends for Albireo Pharma.

Which institutional investors are selling Albireo Pharma stock?

ALBO stock was sold by a variety of institutional investors in the last quarter, including Chicago Capital LLC. Company insiders that have sold Albireo Pharma company stock in the last year include Patrick Taylor Horn and Simon NR Harford. View Insider Buying and Selling for Albireo Pharma.

Which institutional investors are buying Albireo Pharma stock?

ALBO stock was purchased by a variety of institutional investors in the last quarter, including Alpine Global Management LLC. Company insiders that have bought Albireo Pharma stock in the last two years include Life Sciences Maste Perceptive and Ronald Harold Wilfred Cooper. View Insider Buying and Selling for Albireo Pharma.

How do I buy shares of Albireo Pharma?

Shares of ALBO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Albireo Pharma's stock price today?

One share of ALBO stock can currently be purchased for approximately $23.65.

How big of a company is Albireo Pharma?

Albireo Pharma has a market capitalization of $300.12 million and generates $12.74 million in revenue each year. The biopharmaceutical company earns $-46,110,000.00 in net income (profit) each year or ($3.94) on an earnings per share basis. Albireo Pharma employs 39 workers across the globe.View Additional Information About Albireo Pharma.

What is Albireo Pharma's official website?

The official website for Albireo Pharma is http://www.albireopharma.com/.

How can I contact Albireo Pharma?

Albireo Pharma's mailing address is 10 POST OFFICE SQUARE SUITE 502 SOUTH, BOSTON MA, 02109. The biopharmaceutical company can be reached via phone at 857-254-5555 or via email at [email protected]


MarketBeat Community Rating for Albireo Pharma (NASDAQ ALBO)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  244 (Vote Outperform)
Underperform Votes:  267 (Vote Underperform)
Total Votes:  511
MarketBeat's community ratings are surveys of what our community members think about Albireo Pharma and other stocks. Vote "Outperform" if you believe ALBO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALBO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/24/2020 by MarketBeat.com Staff

Featured Article: Sell-Side Analysts

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel